You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME/CE

Managing Pain Patients Who Abuse Prescription Drugs

  • Authors: Gayathri J. Dowling, PhD; Richard A. Denisco, MD
  • CME/CE Released: 9/26/2012; Reviewed and Renewed: 10/2/2014
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 10/2/2015, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care providers, neurologists, anesthesiologists, pain specialists, obstetrician/gynecologists, orthopedists, nurse practitioners, nurses and other healthcare practitioners who manage patients with chronic pain.

The goal of this activity is to describe the symptoms and prevalence of opioid addiction and dependence in patients with chronic pain, and the steps clinicians can take to screen for, prevent, and treat such these conditions.

Upon completion of this activity, participants will be able to:

  1. Develop strategies to assess and monitor patients taking opioids for abuse and potential diversion of medication
  2. Propose communication strategies to engage patients in dialog focused on treatment of prescription drug abuse or addiction
  3. Formulate treatment management and possible referral plans to prevent and address opioid addiction in patients with a diagnosis of chronic pain


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Gayathri J. Dowling, PhD

    Acting Chief, Science Policy Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

    Disclosures

    Disclosure: Gayathri J. Dowling, PhD has disclosed no relevant financial relationships.

    Dr Dowling does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Dowling does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Richard A. Denisco, MD

    Medical Officer, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

    Disclosures

    Disclosure: Richard A. Densico, MD, has disclosed no relevant financial relationships.

    Dr. Denisco does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr. Denisco does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

  • Jane Lowers

    Group Scientific Director, Medscape LLC

    Disclosures

    Disclosure: Jane Lowers has disclosed no relevant financial relationships.

  • Colleen Quinn

    Clinical Editor, Medscape, LLC

    Disclosures

    Disclosure: Colleen Quinn has disclosed no relevant financial relationships.

Writer(s)

  • Lynne Kolton Schneider, PhD

    Freelance writer, Boca Raton, Florida

    Disclosures

    Disclosure: Lynne Kolton Schneider has disclosed no relevant financial relationships.

Additional Planners/Reviewers

  • Robert Carroll, PhD, RN

    Project director, IQ Solutions, Rockville, MD

    Disclosures

    Disclosure: Robert Carroll, PhD, RN, has disclosed no relevant financial relationships.

  • Denise Crute, MA

    Director of training, IQ Solutions, Rockville, MD

    Disclosures

    Disclosure: Denise Crute, MA has disclosed no relevant financial relationships.

  • Bill H. McCarberg, MD

    Primary Care Physician, Adjunct Assistant Clinical Professor, University of California, San Diego; Founder, Chronic Pain Management Program, Kaiser Permanente, San Diego, California

    Disclosures

    Disclosure: Bill McCarberg, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: PriCara; Forest Laboratories, Inc.; Endo Pharmaceuticals; Sucampo Pharmaceuticals, Inc.; NeurogesX, Inc.; Teva Pharmaceuticals; Insys Therapeutics, Inc; QRX Pharma Ltd; Salix Pharmaceuticals, Inc.

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner

  • Laurie E. Scudder, DNP, NP

    Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

    Disclosures

    Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 1.75 contact hour(s) of continuing nursing education for RNs and APNs; 1.75 of these credits is in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME/CE

Managing Pain Patients Who Abuse Prescription Drugs

Authors: Gayathri J. Dowling, PhD; Richard A. Denisco, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME/CE Released: 9/26/2012; Reviewed and Renewed: 10/2/2014

Valid for credit through: 10/2/2015, 11:59 PM EST

processing....

Screening Tools

Sample Treatment Agreements

Opioid and pain treatment agreement samples

Other Modules from the NIDA Centers of Excellence

Tools to Assess Drug Use

Training for Physicians Who Wish to Prescribe Methadone and Buprenorphine

  • SAMHSA Helps Bring Buprenorphine to the Field/Training Physicians
    This article describes how to comply with the Drug Addiction Treatment Act of 2000 for physicians who want to prescribe the medication for detoxification or maintenance treatment for patients with drug addictions.
  • Physician Waiver Qualifications
    This page describes the qualifications a physician must have to obtain a waiver to prescribe the medication for detoxification or maintenance treatment for patients with drug addictions.
  • How to Obtain a Waiver
    The page describes the actions a physician must take to obtain a waiver.

Substance Abuse Treatment Resources

Information About Safe Medication Disposal

« Return to: Managing Pain Patients Who Abuse Prescription Drugs
  • Print